{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:22:55Z","timestamp":1773872575318,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00381-017-3690-9","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T05:18:00Z","timestamp":1513142280000},"page":"777-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome"],"prefix":"10.1007","volume":"34","author":[{"given":"Mohammad H.","family":"Abu Arja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne E.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Salceda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahd","family":"Al-Sufiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Bou\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"key":"3690_CR1","doi-asserted-by":"publisher","unstructured":"Sugimoto K, Ideguchi M, Sadahiro H, Yoshikawa K, Goto H, Nomura S, Fujii M, Suzuki M (2013) Yolk sac tumor of the bilateral basal ganglia in a patient with Down syndrome. Brain Tumor Pathol 30(4):247\u2013252. \nhttps:\/\/doi.org\/10.1007\/s10014-012-0134-9","DOI":"10.1007\/s10014-012-0134-9"},{"key":"3690_CR2","doi-asserted-by":"publisher","unstructured":"Satg\u00e9 D, Monteil P, Sasco AJ, Vital A, Ohgaki H, Geneix A, Malet P, Vekemans M, R\u00e9thor\u00e9 MO (2001) Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing grade 2 astrocytoma. Cancer 91(8):1458\u20131466. \nhttps:\/\/doi.org\/10.1002\/1097-0142(20010415)91:8<1458::AID-CNCR1153>3.0.CO;2-B","DOI":"10.1002\/1097-0142(20010415)91:8%3C1458::AID-CNCR1153%3E3.0.CO;2-B"},{"key":"3690_CR3","doi-asserted-by":"publisher","unstructured":"Junqueira PA and Moura-Ribeiro MVLd (2002) Moyamoya and Down syndrome: study conducted by meta-analysis. Arq Neuropsiquiatr 2002;60(2A):274\u2013280, DOI: \nhttps:\/\/doi.org\/10.1590\/S0004-282X2002000200017","DOI":"10.1590\/S0004-282X2002000200017"},{"issue":"2","key":"3690_CR4","first-page":"63","volume":"102","author":"V Borchgrave de","year":"2002","unstructured":"de Borchgrave V, Saussu F, Depre A, de Barsy T (2002) Moyamoya disease and Down syndrome: case report and review of the literature. Acta Neurol Belg 102(2):63\u201366","journal-title":"Acta Neurol Belg"},{"key":"3690_CR5","doi-asserted-by":"publisher","unstructured":"Dai AI, Shaikh ZA, Cohen ME (2000) Early-onset moyamoya syndrome in a patient with Down syndrome: case report and review of the literature. J Child Neurol 15(10):696\u2013699. \nhttps:\/\/doi.org\/10.1177\/088307380001501012","DOI":"10.1177\/088307380001501012"},{"issue":"1","key":"3690_CR6","first-page":"63","volume":"9","author":"C Fung","year":"2003","unstructured":"Fung C, Kwong K, Tsui E, Wong S (2003) Moyamoya syndrome in a child with Down syndrome. Hong Kong Med J 9(1):63\u201366","journal-title":"Hong Kong Med J"},{"key":"3690_CR7","doi-asserted-by":"publisher","unstructured":"Phi JH, Wang K-C, Lee JY, Kim S-K (2015) Moyamoya syndrome: a window of moyamoya disease. J Korean Neurosurg Soc 57(6):408\u2013414. \nhttps:\/\/doi.org\/10.3340\/jkns.2015.57.6.408","DOI":"10.3340\/jkns.2015.57.6.408"},{"key":"3690_CR8","doi-asserted-by":"publisher","unstructured":"Calaminus G, Frappaz D, Kortmann RD, Krefeld B, Saran F, Pietsch T, Vasiljevic A, Garre ML, Ricardi U, Mann JR, G\u00f6bel U, Alapetite C, Murray MJ, Nicholson JC (2017) Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology 19(12):1661\u20131672. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nox122","DOI":"10.1093\/neuonc\/nox122"},{"key":"3690_CR9","doi-asserted-by":"publisher","unstructured":"Matsutani M (2004) Clinical management of primary central nervous system germ cell tumors. Semin Oncol 31(5):676\u2013683. \nhttps:\/\/doi.org\/10.1053\/j.seminoncol.2004.07.010","DOI":"10.1053\/j.seminoncol.2004.07.010"},{"key":"3690_CR10","doi-asserted-by":"publisher","unstructured":"Berger GK, Gee K, Votruba C, McBride A, Anwer F (2017) Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: a focus review of the literature. Crit Rev Oncol Hematol 113:8\u201317. \nhttps:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.021","DOI":"10.1016\/j.critrevonc.2017.02.021"},{"key":"3690_CR11","doi-asserted-by":"publisher","unstructured":"Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD (2011) CD30: an important new target in hematologic malignancies. Leuk Lymphoma 52(9):1641\u20131654. \nhttps:\/\/doi.org\/10.3109\/10428194.2011.574761","DOI":"10.3109\/10428194.2011.574761"},{"key":"3690_CR12","doi-asserted-by":"publisher","unstructured":"Squillante CM, Vaughn DJ (2015) Targeted therapies in germ cell tumors. Urol Oncol 33(8):363\u2013369. \nhttps:\/\/doi.org\/10.1016\/j.urolonc.2014.09.008","DOI":"10.1016\/j.urolonc.2014.09.008"},{"key":"3690_CR13","doi-asserted-by":"publisher","unstructured":"Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Far\u00e8 E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A (2013) Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment. J Urol 190(5):1919\u20131924. \nhttps:\/\/doi.org\/10.1016\/j.juro.2013.04.057","DOI":"10.1016\/j.juro.2013.04.057"},{"key":"3690_CR14","doi-asserted-by":"publisher","unstructured":"Ansell SM (2014) Brentuximab vedotin. Blood 124(22):3197\u20133200. \nhttps:\/\/doi.org\/10.1182\/blood-2014-06-537514","DOI":"10.1182\/blood-2014-06-537514"},{"key":"3690_CR15","doi-asserted-by":"crossref","unstructured":"Albany C, Feldman DR, Garbo LE and Einhorn LH (2013) Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors. J Clin Oncol 31:6_suppl, 327\u2013327","DOI":"10.1200\/jco.2013.31.6_suppl.327"},{"key":"3690_CR16","doi-asserted-by":"publisher","unstructured":"Necchi A, Anichini A, Raggi D, Giannatempo P, Magazz\u00f9 D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM (2016) Brentuximab vedotin in CD30-expressing germ cell tumors after chemotherapy failure. Clin Genitourin Cancer 14(4):261\u2013264. \nhttps:\/\/doi.org\/10.1016\/j.clgc.2016.03.020","DOI":"10.1016\/j.clgc.2016.03.020"},{"key":"3690_CR17","doi-asserted-by":"publisher","unstructured":"Abid MB, Wang S, Loi HY, Poon L (2016) ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol 95(10):1725\u20131726. \nhttps:\/\/doi.org\/10.1007\/s00277-016-2746-3","DOI":"10.1007\/s00277-016-2746-3"},{"key":"3690_CR18","unstructured":"Carson KR1, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O and Bennett CL (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120(16):2464\u20132471"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00381-017-3690-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-017-3690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-017-3690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T07:54:58Z","timestamp":1521186898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00381-017-3690-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1007\/s00381-017-3690-9","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,13]]}}}